Cover Story
Clinical
HRD results can vary widely, depending on what assay you choose—even as they guide treatment choices
Homologous recombination deficiency tests are used routinely in the clinic to determine which patients get PARP inhibitors.
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
CURRENT ISSUE
CURRENT ISSUE
Trending Stories
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Over three years as CEO, Karen Knudsen led ACS through COVID—and reversed the charity’s long slump
- Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity
- 2024 Karnofsky Award winner Lillian Siu talks about her career in phase I studies, ctDNA, and her mentor’s “evil red pencil”
- Biotech companies, investors pour billions into mRNA vaccines as research ramps up in cancer and non-communicable diseases